Stockreport

Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer

Aravive, Inc.  (ARAV) 
Last aravive, inc. earnings: 3/27 08:00 am Check Earnings Report
PDF Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abs [Read more]